Participants who recovered from COVID-19 COVID-19 Vaccine SARS-CoV-2 Antibody Cellular immunity Post COVID-19 intramuscular intradermal
Conditions
Interventions
one dose of 0.1 ml ChAdOx1/AZD1222 (AstraZeneca) intradermal route,one dose of 0.25 ml ChAdOx1/AZD1222 (AstraZeneca) intramuscular route,one dose of 0.5 ml ChAdOx1/AZD1222 (AstraZeneca) intramuscular
Dose-sparing intradermal route,Dose-sparing intramuscular route,Regular intramuscular route
Sponsors
National Research Council of Thailand (NRCT)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age 18 years or more 2. Recovered from COVID-19 for at least 3 months 3. Eligible for AstraZeneca Vaccination 4. Informed consent for participation
Exclusion criteria
Exclusion criteria: History of allergy to a component of ChAdOx1/AZD1222 (AstraZeneca)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SARS-CoV-2 antibodies Before vaccination, 4 weeks post vaccination IgG (ELISA), Neutralizing antibody (NeutraLISA) | — |
Secondary
| Measure | Time frame |
|---|---|
| Cellular immunity Before vaccination, 4 weeks post vaccination T cell (Fluorospot), Memory B cell (Fluorospot),COVID-19 infection rate 1 day post vaccination, 7 days post vaccination, 4 weeks post vaccination Symptom Assessment and confirmed with Real-time RT-PCR if suspected,Adverse events On vaccination day, 1 day post vaccination, 7 days post vaccination, 4 weeks post vaccination Patient report outcomes | — |
Countries
Thailand
Contacts
Public ContactWisit Prasitsirikul
Bamrasnaradura Infectious Diseases Institute
Outcome results
None listed